Recent content by InNeedOfHelp

  1. I

    I have no experience for this drug. For sleep I would say melatonin 1-2mg is the least harmful...

    I have no experience for this drug. For sleep I would say melatonin 1-2mg is the least harmful and can be bought anywhere in NL. I am on nortryptiline for different reasons and I find it manageable. Everyone reacts different to each medicine. There is a big chance your tinnitus will stay as it is.
  2. I

    Sounds like fleeting tinnitus (sudden brief unilateral tapering tinnitus). Interesting as we...

    Sounds like fleeting tinnitus (sudden brief unilateral tapering tinnitus). Interesting as we don't know what causes that. I'd not consider fleeting tinnitus a spike personally. I think the least impactful sleeping med is Melatonine 2MG. This is used for jetlags and is available without...
  3. I

    I didn't after that. Are you talking about fleeting tinnitus (seconds of tonal spike) or a long...

    I didn't after that. Are you talking about fleeting tinnitus (seconds of tonal spike) or a long spike? I experienced also increased tinnitus from Amitryptiline and Carbamazepine. Both of them died down within 2 weeks after stopping. It seems I'm very sensitive for meds.
  4. I

    New University of Michigan Tinnitus Discovery — Signal Timing

    I still cannot understand why people are supporting the slow-paced release and the strategy of Auricle trying to launch the device themselves. Plenty of pharmaceuticals are approved within six months of finishing their Phase 3 trials. Consider the pain medication Suzetrigine (VX-548), which just...
  5. I

    Xenon Pharmaceuticals' XEN1101 — Kv7 Potassium Channel Modulator

    It's not 15 months away, but it's the closest so far. It's the only pill in Phase 3 where we are 100% sure that some people will benefit from it. Some people have achieved silence or near silence using Retigabine. Not a single pill in trials now or on the market available has ever been able to...
  6. I

    Xenon Pharmaceuticals' XEN1101 — Kv7 Potassium Channel Modulator

    It's adjusted one quarter back, unfortunately. Yes, I think this is our only bet in the coming 12-15 months. Calming down hyperexcitability is the key to curing many diseases, epilepsy, pain, Alzheimer's, tinnitus... I do, despite the fact that no one talks about EMA approval in any of their...
  7. I

    Xenon Pharmaceuticals' XEN1101 — Kv7 Potassium Channel Modulator

    From the Q4 investors call this week:
  8. I

    TU Delft & Prof. Dirk De Ridder — Bimodal Stimulation Device for Treating Tinnitus

    I might visit the symposium, I live 30 minutes away. Thanks for sharing.
  9. I

    Evidence of Cochlear Neural Degeneration in Normal-Hearing Subjects with Tinnitus

    I think reactivity is caused by hair cells that are damaged/vulnerable but not yet broken. These hair cells are much more susceptible to noise trauma. Over time they either break down (worsening early on) or stabilize (less reactive/strengthened) but are still easy to break. They are essentially...
  10. I

    New University of Michigan Tinnitus Discovery — Signal Timing

    That is approval to trial. Not approval to market.
  11. I

    New University of Michigan Tinnitus Discovery — Signal Timing

    Fits like a glove to Auricle. Trade/Device Name: Lenire Regulation Number: 21 CFR 874.3410 Regulation Name: Combined acoustic and electrical external stimulation device for the relief of tinnitus Regulatory Class: Class II Product Code: QVN From...
  12. I

    New University of Michigan Tinnitus Discovery — Signal Timing

    It is completely normal to submit almost 2 years after completing your final trial to the FDA for a class II device which has an equivalent substitute? Biggest BS in this thread so far. They had plenty of time to make pre-arrangements. They had plenty of time to fundraise through corporations...
  13. I

    Oral Gabapentin and Intradermal Injection of Lidocaine: A Role for the Treatment of Tinnitus?

    The results are promising but as with 99% of all research, it will likely not be followed up. I don't see why it would bring lasting effects for that long, looking at the half life of these drugs. I don't see anything on inducing neuroplasticity in the article. I'm personally very hesitant with...
  14. I

    Xenon Pharmaceuticals' XEN1101 — Kv7 Potassium Channel Modulator

    → Saniona’s CEO: ”Selectivity is the cornerstone of future epilepsy treatments” Saniona is next in line to develop a Kv7.2 drug. This one is still far out though. From my understanding, there are now four in trials US/Worldwide, one in China and one starting in the near future.
  15. I

    Xenon Pharmaceuticals' XEN1101 — Kv7 Potassium Channel Modulator

    Second half 2024 could be anywhere between July and December. Trial completion will be at the end of 2024. Best case scenario would be essentially a December 2024/January 2025 data readout, worst case scenario data readout summer 2025. XEN1101 does not have FDA Fast Track. I'm still hoping...
See more
Top Bottom
Back
Forums
Members
Donate
Menu